OPEN END-TURBO-OPTIONSSCHEIN - GILEAD SCIENCES | Market Closed - BOERSE MUENCHEN 15:36:10 2024-06-14 EDT | ||
| 10.65 EUR | +17.81% |
|
| Current month | +15.14% | ||
| 1 month | -17.76% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 10.65 | +17.81% |
| 24-06-13 | 9.04 | -2.38% |
| 24-06-12 | 9.26 | -6.46% |
| 24-06-11 | 9.9 | -3.51% |
| 24-06-10 | 10.26 | +2.81% |
Real-time BOERSE MUENCHEN
Last update June 14, 2024 at 03:36 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | HSBC |
| WKN | TT4Q9G |
| ISIN | DE000TT4Q9G0 |
| Date issued | 2020-11-11 |
| Strike | 53.6 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 8.03 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 37.31 € |
|---|---|
| Lowest since issue | 6.05 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.06
USD
Average target price
82.7
USD
Spread / Average Target
+27.11%
- Stock Market
- Certificates
- Certificat
